Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 1:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Double Blind Varenicline Clear all
Completed Phase 3 Interventional

A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline

NCT00143299
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
8
States / cities
Denver, Colorado • Milford, Massachusetts • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2007 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence

NCT01680887
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

NCT00285012
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, Varenicline Tartarate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2010 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Varenicline to Reduce Alcohol Consumption in Heavy Drinkers

NCT00695500
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Vijay Ramchandani, Ph.D.
NIH
Eligibility
21 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2016 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers

NCT00463918
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 16 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
15
States / cities
Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 4 Interventional

Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia

NCT00727103
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Alcohol Dependence, Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

Smoking Cessation Study In Healthy Adolescent Smokers

NCT01312909
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline 1mg BID, Varenicline 0.5mg BID, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 19 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
56
States / cities
Ozark, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider

NCT01244061
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Los Angeles, California • DeLand, Florida • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Varenicline for the Treatment of Smokeless Tobacco

NCT00813917
View directory record Official record
Conditions
Nicotine Dependence
Interventions
varenicline, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

Chantix for Treating Cocaine Dependence

NCT00567008
View directory record Official record
Conditions
Cocaine Dependence
Interventions
varenicline, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 2 Interventional

A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

NCT00150241
View directory record Official record
Conditions
Smoking Cessation
Interventions
CP-526,555 (varenicline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
7
States / cities
Los Angeles, California • Farmington, Connecticut • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo

NCT00749944
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 2 Interventional

12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.

NCT00150254
View directory record Official record
Conditions
Smoking Cessation
Interventions
CP-526,555 (varenicline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
13
States / cities
Los Angeles, California • San Bernardino, California • Upland, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2007 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

Varenicline for Alcohol Dependence

NCT01146613
View directory record Official record
Conditions
Alcoholism
Interventions
Varenicline, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Baltimore, Maryland • Boston, Massachusetts • Bedford, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2014 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 2 Interventional

12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation

NCT00150228
View directory record Official record
Conditions
Smoking Cessation
Interventions
CP-526,555 (varenicline)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
7
States / cities
Lexington, Kentucky • Albert Lea, Minnesota • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2007 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

Varenicline (Chantix™) for the Treatment of Alcohol Dependence

NCT00705523
View directory record Official record
Conditions
Alcoholism
Interventions
varenicline, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date

NCT00691483
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Litchfield Park, Arizona • Los Angeles, California • Santa Ana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder

NCT01010204
View directory record Official record
Conditions
Smoking Cessation, Bipolar Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
K.N. Roy Chengappa
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
DuBois, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2017 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

Varenicline for Nicotine Vaping Cessation in Adolescents

NCT05367492
View directory record Official record
Conditions
Vaping, Nicotine Dependence
Interventions
Double Blind Varenicline, Double Blind Placebo, QuitVaping, This Is Quitting
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years to 25 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

NCT00644969
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Aurora, Colorado • Farmington, Connecticut • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 4 Interventional Results available

A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction

NCT01370356
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline Tartrate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Encino, California • Newport Beach, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2014 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 2 Interventional Results available

Varenicline vs Placebo for the Treatment of Methamphetamine Dependence

NCT01011829
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Varenicline, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 27, 2026, 1:53 PM EDT
Completed Phase 3 Interventional

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

NCT00143364
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
15
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2007 · Synced Sep 27, 2026, 1:53 PM EDT